Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

PRIMARY OBJECTIVE: I. To estimate the 2-year progression free survival. SECONDARY OBJECTIVES: II. To estimate the 2-year overall survival. III. To estimate the 2-year cumulative incidence of progression. IV. To estimate time to hematopoietic recovery, using absolute neutrophil and platelet engraftment. V. To estimate incidence of grade 3-4 toxicities by Bearman Scale, Day 0 to Day 100. VI. To estimate the response rate (CR/PR). VII. To estimate 100-day treatment related mortality. VIII. To estimate incidence of myelodysplasia and therapy related acute myeloid leukemia (AML). IX. To descriptively compare the outcomes of patients treated on this protocol to a comparable patient population treated with chemotherapy alone. OUTLINE: RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan intravenously (IV) following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily (BID) and cytarabine IV over 2 hours BID on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8\*. NOTE: \* Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.